Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03505320
Title A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (ILUSTRO)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Zolbetuximab

Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab

Pembrolizumab + Zolbetuximab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA


No variant requirements are available.